Literature DB >> 21351083

UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer.

Alexandros Daskalos1, Urszula Oleksiewicz, Anastasia Filia, George Nikolaidis, George Xinarianos, John R Gosney, Angeliki Malliri, John K Field, Triantafillos Liloglou.   

Abstract

BACKGROUND: The UHRF1 gene possesses an essential role in DNA methylation maintenance, but its contribution to tumor suppressor gene hypermethylation in primary human cancers currently remains unclear.
METHODS: mRNA expression levels of UHRF1, DNMT1, DNMT3A, DNMT3B, and E2F1 were evaluated in 105 primary nonsmall cell lung carcinomas by quantitative polymerase chain reaction. The methylation status of CDKN2A and RASSF1 promoters was examined by pyrosequencing. UHRF1 was knocked down by short hairpin RNA in A549 lung adenocarcinoma cells.
RESULTS: All 4 genes were overexpressed in a coordinated manner in the lung tumor tissues, and their expression correlated with that of E2F1. Higher UHRF1 expression in tumor tissues correlated with the hypermethylation of CDKN2A (P = .005) and RASSF1 promoters (P = .034), and the relationship with a combined epigenotype was even stronger (P = 2.3 × 10(-4) ). When UHRF1 was knocked down in A549 lung adenocarcinoma cells, lower methylation levels of RASSF1, CYGB, and CDH13 promoters were observed. Also, UHRF1 knockdown clones demonstrated reduced proliferation and decreased cell migration properties.
CONCLUSIONS: Our data demonstrate that UHRF1 is a key epigenetic switch, which controls cell cycle in nonsmall cell lung carcinoma through its ability to sustain the transcriptional silencing of tumor suppressor genes by maintaining their promoters in a hypermethylated status. Thus, UHRF1 should be considered, along with DNMTs, among the potential targets for cancer treatment and/or therapeutic stratification.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21351083     DOI: 10.1002/cncr.25531

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  55 in total

Review 1.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.

Authors:  Mahmoud Alhosin; Tanveer Sharif; Marc Mousli; Nelly Etienne-Selloum; Guy Fuhrmann; Valérie B Schini-Kerth; Christian Bronner
Journal:  J Exp Clin Cancer Res       Date:  2011-04-15

3.  The Roles of the Methyl-CpG Binding Proteins in Cancer.

Authors:  Lee Parry; Alan R Clarke
Journal:  Genes Cancer       Date:  2011-06

Review 4.  Zebrafish Discoveries in Cancer Epigenetics.

Authors:  Yelena Chernyavskaya; Brandon Kent; Kirsten C Sadler
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  Comparative Proteomics of Dying and Surviving Cancer Cells Improves the Identification of Drug Targets and Sheds Light on Cell Life/Death Decisions.

Authors:  Amir Ata Saei; Pierre Sabatier; Ülkü Güler Tokat; Alexey Chernobrovkin; Mohammad Pirmoradian; Roman A Zubarev
Journal:  Mol Cell Proteomics       Date:  2018-03-23       Impact factor: 5.911

6.  RFTS-deleted DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation.

Authors:  Bo-Kuan Wu; Szu-Chieh Mei; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer.

Authors:  Chun-I Wang; Kun-Yi Chien; Chih-Liang Wang; Hao-Ping Liu; Chia-Chen Cheng; Yu-Sun Chang; Jau-Song Yu; Chia-Jung Yu
Journal:  Mol Cell Proteomics       Date:  2012-07-25       Impact factor: 5.911

8.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

9.  Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients.

Authors:  Penny Nymark; Mervi Aavikko; Jussi Mäkilä; Salla Ruosaari; Tuija Hienonen-Kempas; Harriet Wikman; Kaisa Salmenkivi; Risto Pirinen; Antti Karjalainen; Esa Vanhala; Eeva Kuosma; Sisko Anttila; Eeva Kettunen
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

10.  Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation.

Authors:  Zhen-Yu Zhang; Jia-Jun Cai; Jin Hong; Kay Ka-Wai Li; Zhou Ping; Yin Wang; Ho-Keung Ng; Yu Yao; Ying Mao
Journal:  Med Oncol       Date:  2016-07-23       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.